NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
Clinical Trials
6 trialsNCT02632708 2025-04-11
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
Servier
Phase 1 Active not recruiting
NCT01915498 2024-10-22
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Celgene
Phase 1/2 Completed
NCT03720366 2024-02-28
A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients
Celgene
Phase 1 Completed
NCT04075747 2023-10-16
V-FAST
Jazz Pharmaceuticals
Phase 1 Completed
NCT02273739 2021-02-23
Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Celgene
Phase 1/2 Completed